Gilead Sciences Inc (GILD) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: -$6.75 (est. -$7.14) — inline Revenue: $7.80B (est. $7.40B) — inline Reported: 2026-08-04 Recent Quarters Q1 FY26 (2026-05-07): EPS $2.03 vs est $1.91 · Rev $6.96B vs est $6.92B Q4 FY25 (2026-02-10): EPS $1.86 vs est $1.83 · Rev $7.92B vs est $7.64B Q3 FY25 (2025-10-30): EPS $2.47 vs est $2.14 · Rev $7.77B vs est $7.46B Q2 FY25 (2025-08-07): EPS $2.01 vs est $1.95 · Rev $7.08B vs est $6.96B About Gilead Sciences Inc Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and brea...